Trial: Phase III, Open-label, Study of First-l…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: April 11, 2024

Planned enrollment: 675

Trial ID: NCT06357533

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Datopotamab deruxtecan (Dato‑DXd; DS‑1062; US brand name Datroway) is a TROP2‑directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca. In the United States, it is FDA‑approved for: - Unresectable or metastatic HR‑positive/HER2‑negative breast cancer after prior endocrine therapy and chemotherapy (January 17, 2025). (fda.gov) - Locally advanced or metastatic EGFR‑mutated NSCLC after prior EGFR‑directed therapy and platinum chemotherapy (accelerated approval, June 23, 2025). (fda.gov)

Large phase 3 trials have reported improved progression‑free survival vs chemotherapy in HR+/HER2− breast cancer (TROPION‑Breast01) and in previously treated NSCLC overall (TROPION‑Lung01), with the clearest benefit in nonsquamous NSCLC; overall survival in Lung01 did not reach statistical significance in the all‑comers population. (ascopubs.org)

Mechanism of action

Dato‑DXd is a humanized anti‑TROP2 IgG1 linked via a cleavable tetrapeptide linker to a membrane‑permeable topoisomerase I inhibitor payload (DXd); the average drug–antibody ratio is ~4. Upon TROP2 binding and internalization, lysosomal cleavage releases DXd, causing DNA damage and apoptosis. Preclinical studies also show “bystander” killing of adjacent low‑TROP2 tumor cells. (pubmed.ncbi.nlm.nih.gov)

Dosing used in pivotal trials and in US labeling is 6 mg/kg IV every 3 weeks (capped at 540 mg for ≥90 kg). (pubmed.ncbi.nlm.nih.gov)

Efficacy

Breast cancer (HR+/HER2−, previously treated) - TROPION‑Breast01 (phase 3, n≈732): Dato‑DXd significantly improved PFS vs investigator’s‑choice single‑agent chemotherapy (BICR HR 0.63; 95% CI 0.52–0.76; median 6.9 vs 4.9 months). Confirmed ORR 36.4% vs 22.9%. OS was immature at the primary analysis (HR 0.84; 95% CI 0.62–1.14). These data supported the US approval. (ascopubs.org)

NSCLC (previously treated, all histologies) - TROPION‑Lung01 (phase 3, n=604): PFS benefit vs docetaxel (median 4.4 vs 3.7 months; HR 0.75; P=0.004); OS not statistically significant in the overall population (median 12.9 vs 11.8 months; HR 0.94; P=0.53). Benefit was most pronounced in nonsquamous NSCLC. (pubmed.ncbi.nlm.nih.gov)

NSCLC (nonsquamous subgroup from Lung01; descriptive) - Nonsquamous subgroup showed higher activity: ORR 31.2% vs 12.8% with docetaxel; median PFS 5.5 vs 3.6 months; OS 14.6 vs 12.3 months (HR 0.84). OS did not meet significance in the overall study. (iaslc.org)

EGFR‑mutated NSCLC (post‑EGFR TKI and platinum) - Pooled analysis (TROPION‑Lung05 phase 2 + Lung01 subset; n≈117): confirmed ORR 42.7% (95% CI 33.6–52.2), median DOR 7.0 months, median PFS 5.8 months, median OS 15.6 months. These data supported the US accelerated approval. (daiichisankyo.us)

Early‑phase breast cancer cohorts - TROPION‑PanTumor01 (phase 1): in heavily pretreated HR+/HER2− and TNBC cohorts, BICR ORR 26.8% and 31.8%, with median PFS 8.3 and 4.4 months, respectively. (ascopubs.org)

Safety

Class‑consistent risks include stomatitis/oral mucositis, nausea, ocular events, alopecia, and interstitial lung disease (ILD)/pneumonitis.

Breast (TROPION‑Breast01): grade ≥3 treatment‑related AEs were lower with Dato‑DXd vs chemo (20.8% vs 44.7%). Additional safety analyses reported stomatitis/oral mucositis in 56%, ocular events in 40%, and adjudicated drug‑related ILD in 3% (mostly low grade). (ascopubs.org)
NSCLC (TROPION‑Lung01): stomatitis ~47% and nausea ~34% with Dato‑DXd; grade ≥3 TRAEs 26% vs 42% with docetaxel; pneumonitis/ILD ~4%. No late safety signals with extended follow‑up. (ascopost.com)
Stomatitis management and incidence across trials are detailed in a peer‑reviewed review and show mostly grade 1–2 events with early onset; implementation of prophylaxis/management guidelines reduced frequency and severity. (academic.oup.com)
Pooled ILD analysis across breast and lung trials reported adjudicated drug‑related ILD in ~5% (mostly grade 1–2), with rare grade ≥3 events; careful monitoring is recommended. US labeling includes boxed/serious warnings for ILD/pneumonitis, ocular adverse reactions, and stomatitis. (ovid.com)

Show for: Rilvegostomig (AZD2936)

Overview

Rilvegostomig (AZD2936) is an investigational bispecific monoclonal antibody from AstraZeneca that targets PD‑1 and TIGIT. It is being studied across multiple tumor types, with ongoing phase 3 programs including first‑line metastatic non‑squamous NSCLC (ARTEMIDE‑Lung03), adjuvant biliary tract cancer after resection (ARTEMIDE‑Biliary01), first‑line advanced hepatocellular carcinoma (ARTEMIDE‑HCC01), and first‑line HER2‑positive, PD‑L1–positive gastric/GEJ cancer (ARTEMIDE‑Gastric01). (cdek.pharmacy.purdue.edu)

Mechanism of action

Bispecific IgG1 engineered to bind PD‑1 and TIGIT on the same T cell, aiming to augment antitumor immunity beyond PD‑1 blockade alone. The Fc region carries triple mutations (L234F/L235E/P331S) to reduce Fc‑mediated effector function. (cdek.pharmacy.purdue.edu)
Constructed on a DuetMab backbone; the TIGIT arm derives from Compugen’s anti‑TIGIT antibody (COM902). (cdek.pharmacy.purdue.edu)
Early clinical and translational work suggests high receptor occupancy on peripheral T cells at clinically relevant doses. (pmc.ncbi.nlm.nih.gov)

Efficacy

NSCLC (ARTEMIDE‑01, Phase I/II)

CPI‑pretreated cohort (dose escalation/expansion; PD‑L1 TPS ≥1%): among 83 patients, confirmed ORR 4.8% (all partial responses); median PFS 2.1 months (95% CI 2.0–4.1); 27‑week DCR 31.3%. Recommended phase 2 dose (RP2D) 750 mg Q3W. (oncologypro.esmo.org)
CPI‑naïve cohorts:
PD‑L1 TPS 1–49%: ORR 29%; median PFS 6.0 months (95% CI 2.7–8.4); median DOR 6.4 months (95% CI 4.2–NC). (onclive.com)
PD‑L1 TPS ≥50%: ORR 61.8% (95% CI 43.6–77.8%); median PFS 10.2 months (95% CI 6.3–NC); median DOR 10.3 months (95% CI 8.2–NC). Data are from the first analysis of ARTEMIDE‑01 CPI‑naïve parts C/D and remain preliminary. (onclive.com)

Ongoing phase 3 studies (no efficacy readouts yet)

NSCLC: ARTEMIDE‑Lung03 compares rilvegostomig + platinum/pemetrexed vs pembrolizumab + platinum/pemetrexed in first‑line PD‑L1–positive metastatic non‑squamous NSCLC (started November 2024; target n≈878). (cdek.pharmacy.purdue.edu)
Biliary tract cancer (adjuvant): ARTEMIDE‑Biliary01 evaluates rilvegostomig + investigator’s‑choice chemotherapy (capecitabine, S‑1, or gemcitabine/cisplatin) vs placebo + chemotherapy; primary endpoint recurrence‑free survival (JCO abstract TPS4199; enrollment began 2024; planned n≈750). (ascopubs.org)
Hepatocellular carcinoma: ARTEMIDE‑HCC01 compares rilvegostomig + bevacizumab with or without tremelimumab vs atezolizumab + bevacizumab in first‑line advanced HCC (registered as NCT06921785; launched 2025; planned n≈1220). (smartpatients.com)
Gastric/GEJ (HER2+, PD‑L1 CPS ≥1): ARTEMIDE‑Gastric01 (phase 3) tests rilvegostomig + fluoropyrimidine + trastuzumab deruxtecan vs trastuzumab + chemotherapy + pembrolizumab (3‑arm design; recruiting). (cdek.pharmacy.purdue.edu)

Safety

CPI‑pretreated NSCLC (ARTEMIDE‑01 parts A/B): treatment‑related AEs in 54.2% (grade ≥3 in 8.4%); no grade 4/5 treatment‑related AEs; discontinuations 3.6%. (oncologypro.esmo.org)
CPI‑naïve NSCLC (ARTEMIDE‑01 parts C/D): grade ≥3 treatment‑related AEs 10.5%; treatment‑related discontinuations 4.2%; no clear safety differences between 750 mg and 1500 mg Q3W. (onclive.com)

Key trials (selection)

Phase I/II first‑in‑human NSCLC: ARTEMIDE‑01 (NCT04995523). (cdek.pharmacy.purdue.edu)
Phase III first‑line NSCLC: ARTEMIDE‑Lung03 (NCT06627647). (cdek.pharmacy.purdue.edu)
Phase III adjuvant BTC: ARTEMIDE‑Biliary01 (NCT06109779). (ascopubs.org)
Phase III first‑line HCC: ARTEMIDE‑HCC01 (NCT06921785). (smartpatients.com)
Phase III first‑line HER2+ gastric/GEJ: ARTEMIDE‑Gastric01 (NCT06764875). (cdek.pharmacy.purdue.edu)

HealthScout AI Analysis

Goal: Evaluate whether datopotamab deruxtecan (Dato-DXd) plus the PD-1/TIGIT bispecific antibody rilvegostomig, or rilvegostomig alone, improves clinical outcomes versus pembrolizumab monotherapy as first-line therapy in advanced/metastatic nonsquamous NSCLC with high PD-L1 expression and no actionable genomic alterations.

Patients: Adults with histologically or cytologically confirmed nonsquamous NSCLC, stage IIIB/IIIC or IV not amenable to curative therapy, PD-L1 tumor cell expression ≥50%, no EGFR sensitizing mutations or ALK/ROS1 rearrangements and no other targetable alterations with approved first-line therapy, at least one measurable non-irradiated lesion by RECIST 1.1, ECOG 0–1, and adequate organ function. Key exclusions include squamous histology, prior systemic therapy for advanced disease, active/clinically significant autoimmune disease, uncontrolled comorbidities, active or prior ILD/pneumonitis requiring steroids, significant pulmonary compromise, untreated or symptomatic CNS disease, leptomeningeal disease, significant corneal disease, and uncontrolled infections including HBV/HCV/HIV.

Design: Global, phase III, randomized, open-label, three-arm study with approximately 675 participants. Participants are randomized to Dato-DXd plus rilvegostomig, rilvegostomig monotherapy, or pembrolizumab monotherapy. Efficacy is assessed by blinded independent central review for tumor endpoints.

Treatments: Arm 1: Dato-DXd plus rilvegostomig IV every 3 weeks. Dato-DXd is a TROP2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor (DXd) via a cleavable linker; in previously treated NSCLC (TROPION-Lung01), it improved PFS versus docetaxel with higher response rates and a manageable safety profile, with stomatitis, nausea, and pneumonitis/ILD as key risks. Rilvegostomig (AZD2936) is a bispecific IgG1 antibody targeting PD-1 and TIGIT designed with reduced Fc effector function; early phase data in heavily pretreated NSCLC showed acceptable tolerability, dose-proportional PK, high receptor occupancy at ≥210 mg, and signs of antitumor activity including partial responses and disease control. Arm 2: Rilvegostomig monotherapy IV every 3 weeks. Arm 3: Pembrolizumab monotherapy IV every 3 weeks, a PD-1 inhibitor standard of care for high PD-L1 NSCLC.

Outcomes: Co-primary endpoints are PFS by BICR and OS in the TROP2 biomarker-positive population. Key secondary endpoints include PFS and OS in the full analysis set, ORR and DoR by BICR in TROP2-positive and full populations, patient-reported outcomes (time to deterioration in lung cancer symptoms, GHS/QoL, and physical functioning), PFS2, pharmacokinetics of rilvegostomig and Dato-DXd (including total anti-TROP2 antibody and DXd payload), and immunogenicity (anti-drug antibodies). Safety is assessed by CTCAE v5.0 over approximately 6 years.

Burden on patient: Moderate. Participants require provision of tumor tissue for biomarker testing (PD-L1, TROP2 and others), regular IV infusions every 3 weeks, serial imaging for RECIST assessments, and routine safety labs. Experimental arms include pharmacokinetic and immunogenicity sampling over time, adding blood draws beyond standard care. Patient-reported outcome questionnaires will be administered periodically. Risks specific to Dato-DXd include stomatitis and ILD/pneumonitis, which may necessitate additional monitoring and imaging if respiratory symptoms arise. Travel burden aligns with Q3W infusion schedules and scheduled scans typical of first-line immunotherapy trials.

Last updated: Oct 2025

Eligibility

Show Criteria

Inclusion Criteria:

* Histologically or cytologically documented non-squamous NSCLC.

* Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.

* Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.

* Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.

* Known tumour PD-L1 expression status defined as TC ≥ 50%

* At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline

* ECOG performance status of 0 or 1

* Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention

Exclusion Criteria:

* Prior systemic therapy for advanced/metastatic NSCLC.

* Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.

* History of another primary malignancy within 3 years

* Active or prior documented autoimmune or inflammatory disorders (with exceptions)

* Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.

* Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.

* History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening

* Has significant pulmonary function compromise, as determined by the investigator

* Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.

* History of leptomeningeal carcinomatosis

* Known clinically significant corneal disease

* Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled

* History of active primary immunodeficiency

Sites (269)

Sort by distance to:

Research Site

Melbourne, 3000, Australia

No email / No phone

Status: Withdrawn

Research Site

Gosford, 2250, Australia

No email / No phone

Status: Recruiting

Research Site

Clayton, 3168, Australia

No email / No phone

Status: Recruiting

Research Site

Blacktown, 2148, Australia

No email / No phone

Status: Recruiting

Research Site

Birtinya, 4575, Australia

No email / No phone

Status: Recruiting

Research Site

Wodonga, 3690, Australia

No email / No phone

Status: Recruiting

Research Site

Southport, 4215, Australia

No email / No phone

Status: Withdrawn

Research Site

South Brisbane, QL 4101, Australia

No email / No phone

Status: Recruiting

Research Site

Innsbruck, 6020, Austria

No email / No phone

Status: Recruiting

Research Site

Wels, 4600, Austria

No email / No phone

Status: Recruiting

Research Site

Vienna, 1210, Austria

No email / No phone

Status: Recruiting

Research Site

Vienna, 1140, Austria

No email / No phone

Status: Recruiting

Research Site

Rankweil, 6830, Austria

No email / No phone

Status: Recruiting

Research Site

Linz, 4020, Austria

No email / No phone

Status: Recruiting

Research Site

Krems, 3500, Austria

No email / No phone

Status: Recruiting

Research Site

Hasselt, 3500, Belgium

No email / No phone

Status: Recruiting

Research Site

Liège, 4000, Belgium

No email / No phone

Status: Recruiting

Research Site

La Louvière, 7100, Belgium

No email / No phone

Status: Recruiting

Research Site

Anderlecht, 1070, Belgium

No email / No phone

Status: Withdrawn

Research Site

Natal, 59075-740, Brazil

No email / No phone

Status: Recruiting

Research Site

Ipatinga, 35162-189, Brazil

No email / No phone

Status: Recruiting

Research Site

Florianópolis, 88034-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Curitiba, 80730-150, Brazil

No email / No phone

Status: Recruiting

Research Site

Barretos, 14784-400, Brazil

No email / No phone

Status: Recruiting

Research Site

Porto Alegre, 91350-200, Brazil

No email / No phone

Status: Recruiting

Research Site

Rio de Janeiro, 22211-230, Brazil

No email / No phone

Status: Recruiting

Research Site

Santa Maria, 97015-450, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 01221-020, Brazil

No email / No phone

Status: Recruiting

Research Site

Taubaté, 12030-200, Brazil

No email / No phone

Status: Recruiting

Research Site

Vancouver, British Columbia, VSZ 4E6, Canada

No email / No phone

Status: Recruiting

Research Site

Winnipeg, Manitoba, R3E 0V9, Canada

No email / No phone

Status: Withdrawn

Research Site

St. John's, Newfoundland and Labrador, A1B 3V6, Canada

No email / No phone

Status: Not yet recruiting

Research Site

London, Ontario, N6A 4L6, Canada

No email / No phone

Status: Recruiting

Research Site

Newmarket, Ontario, L3Y 2P9, Canada

No email / No phone

Status: Withdrawn

Research Site

Oshawa, Ontario, L1G 2B9, Canada

No email / No phone

Status: Recruiting

Research Site

Toronto, Ontario, M4N 3M5, Canada

No email / No phone

Status: Withdrawn

Research Site

Trois-Rivières, Quebec, G8Z 3R9, Canada

No email / No phone

Status: Recruiting

Research Site

Rimouski, Quebec, G5L 5T1, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H4J 1C5, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H3T 1M5, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H3T 1E2, Canada

No email / No phone

Status: Recruiting

Research Site

Lévis, Quebec, G6V 0B8, Canada

No email / No phone

Status: Recruiting

Research Site

Saskatoon, Saskatchewan, S7N 4H4, Canada

No email / No phone

Status: Recruiting

Research Site

Chicoutimi, G7H 5H6, Canada

No email / No phone

Status: Recruiting

Research Site

Yangzhou, 225001, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450000, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450008, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610000, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610041, China

No email / No phone

Status: Recruiting

Research Site

Chongqing, 400030, China

No email / No phone

Status: Recruiting

Research Site

Fuzhou, 350014, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510080, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310006, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310016, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310022, China

No email / No phone

Status: Recruiting

Research Site

Harbin, 150049, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230031, China

No email / No phone

Status: Withdrawn

Research Site

Hefei, 230601, China

No email / No phone

Status: Recruiting

Research Site

Jinan, 250117, China

No email / No phone

Status: Recruiting

Research Site

Jining, 272011, China

No email / No phone

Status: Recruiting

Research Site

Kunming, 650118, China

No email / No phone

Status: Recruiting

Research Site

Lanzhou, 730000, China

No email / No phone

Status: Recruiting

Research Site

Linhai, 317000, China

No email / No phone

Status: Recruiting

Research Site

Linyi, 276001, China

No email / No phone

Status: Recruiting

Research Site

Nanjing, 210009, China

No email / No phone

Status: Recruiting

Research Site

Nanning, 530000, China

No email / No phone

Status: Recruiting

Research Site

Nanning, 530021, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200030, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200032, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200433, China

No email / No phone

Status: Recruiting

Research Site

Shenyang, 110022, China

No email / No phone

Status: Recruiting

Research Site

Taiyuan, 030000, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300060, China

No email / No phone

Status: Recruiting

Research Site

Wenzhou, 325000, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430000, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430010, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430022, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 101149, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 100142, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430030, China

No email / No phone

Status: Recruiting

Research Site

Changsha, 410013, China

No email / No phone

Status: Recruiting

Research Site

Xi'an, 710061, China

No email / No phone

Status: Recruiting

Research Site

Kempten, 87439, Germany

No email / No phone

Status: Recruiting

Research Site

Berlin, 10249, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Bonn, 53113, Germany

No email / No phone

Status: Recruiting

Research Site

Düsseldorf, 40489, Germany

No email / No phone

Status: Withdrawn

Research Site

Essen, 45136, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Freiburg im Breisgau, 79106, Germany

No email / No phone

Status: Recruiting

Research Site

Gauting, 82131, Germany

No email / No phone

Status: Recruiting

Research Site

Georgsmarienhütte, 49124, Germany

No email / No phone

Status: Recruiting

Research Site

Gera, 07548, Germany

No email / No phone

Status: Withdrawn

Research Site

Gütersloh, 33332, Germany

No email / No phone

Status: Recruiting

Research Site

Hamburg, 20251, Germany

No email / No phone

Status: Recruiting

Research Site

Hamburg, 22087, Germany

No email / No phone

Status: Recruiting

Research Site

Heidelberg, 69126, Germany

No email / No phone

Status: Recruiting

Research Site

Koblenz, 56068, Germany

No email / No phone

Status: Recruiting

Research Site

Ludwigsburg, 71640, Germany

No email / No phone

Status: Recruiting

Research Site

München, 81925, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Nuremberg, 90419, Germany

No email / No phone

Status: Recruiting

Research Site

Potsdam, 14467, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Ravensburg, 88212, Germany

No email / No phone

Status: Recruiting

Research Site

Szekszárd, 7100, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Törökbálint, 2045, Hungary

No email / No phone

Status: Recruiting

Research Site

Székesfehérvár, 8000, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Budapest, 1121, Hungary

No email / No phone

Status: Recruiting

Research Site

Gyöngyös, 3200, Hungary

No email / No phone

Status: Withdrawn

Research Site

Gyöngyös - Mátraháza, 3200, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Győr, 9024, Hungary

No email / No phone

Status: Recruiting

Research Site

Gyula, 5700, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Kecskemét, 6000, Hungary

No email / No phone

Status: Recruiting

Research Site

Salgótarján, 3100, Hungary

No email / No phone

Status: Recruiting

Research Site

Jaipur, 302004, India

No email / No phone

Status: Recruiting

Research Site

Thiruvananthapuram, 695011, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 11029, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 110085, India

No email / No phone

Status: Recruiting

Research Site

Nashik, 422011, India

No email / No phone

Status: Recruiting

Research Site

Dwārka, 110075, India

No email / No phone

Status: Recruiting

Research Site

Chennai, 600031, India

No email / No phone

Status: Recruiting

Research Site

Kolkata, 700099, India

No email / No phone

Status: Recruiting

Research Site

Nagpur, 440001, India

No email / No phone

Status: Recruiting

Research Site

Marg Jaipur, 302004, India

No email / No phone

Status: Withdrawn

Research Site

Genoa, 16132, Italy

No email / No phone

Status: Recruiting

Research Site

Rozzano, 20089, Italy

No email / No phone

Status: Recruiting

Research Site

Roma, 00128, Italy

No email / No phone

Status: Recruiting

Research Site

Ravenna, 48100, Italy

No email / No phone

Status: Recruiting

Research Site

Pavia, 27100, Italy

No email / No phone

Status: Recruiting

Research Site

Padua, 35128, Italy

No email / No phone

Status: Recruiting

Research Site

Monza, 20052, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Milan, 20162, Italy

No email / No phone

Status: Recruiting

Research Site

Milan, 20141, Italy

No email / No phone

Status: Recruiting

Research Site

Bergamo, 24125, Italy

No email / No phone

Status: Recruiting

Research Site

Tokyo, 104-0045, Japan

No email / No phone

Status: Recruiting

Research Site

Hirakata-shi, 573-1191, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Hirosaki-shi, 036-8563, Japan

No email / No phone

Status: Recruiting

Research Site

Hiroshima, 730-8518, Japan

No email / No phone

Status: Recruiting

Research Site

Kanazawa, 920-8641, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Kashiwa, 227-8577, Japan

No email / No phone

Status: Recruiting

Research Site

Kawasaki-shi, 216-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Kumamoto, 860-8556, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 460-0001, Japan

No email / No phone

Status: Recruiting

Research Site

Niigata, 951-8566, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Okayama, 700-8558, Japan

No email / No phone

Status: Recruiting

Research Site

Osaka, 545-8586, Japan

No email / No phone

Status: Recruiting

Research Site

Osakasayama-shi, 589-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Sagamihara-shi, 252-0375, Japan

No email / No phone

Status: Recruiting

Research Site

Sapporo, 003-0804, Japan

No email / No phone

Status: Recruiting

Research Site

Takaoka-shi, 933-8555, Japan

No email / No phone

Status: Recruiting

Research Site

Takatsuki-shi, 569-8686, Japan

No email / No phone

Status: Recruiting

Research Site

Tokushima, 770-8503, Japan

No email / No phone

Status: Recruiting

Research Site

Hidaka-shi, 350-1298, Japan

No email / No phone

Status: Recruiting

Research Site

Utsunomiya, 320-0834, Japan

No email / No phone

Status: Recruiting

Research Site

Yokohama, 221-0855, Japan

No email / No phone

Status: Recruiting

Research Site

Bunkyō City, 113-8431, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Bunkyō City, 160-0023, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Fukuoka, 812-8582, Japan

No email / No phone

Status: Recruiting

Research Site

Fukuoka, 814-0180, Japan

No email / No phone

Status: Recruiting

Research Site

Poznan, 60-569, Poland

No email / No phone

Status: Recruiting

Research Site

Olsztyn, 10-357, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 02-781, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 01-138, Poland

No email / No phone

Status: Recruiting

Research Site

Przemyśl, 37-700, Poland

No email / No phone

Status: Recruiting

Research Site

San Juan, 00909, Puerto Rico

No email / No phone

Status: Recruiting

Research Site

Seongnam-si, 13496, South Korea

No email / No phone

Status: Recruiting

Research Site

Incheon, 21565, South Korea

No email / No phone

Status: Recruiting

Research Site

Changwon, 51353, South Korea

No email / No phone

Status: Recruiting

Research Site

Suwon, 16499, South Korea

No email / No phone

Status: Recruiting

Research Site

Suwon, 16247, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03722, South Korea

No email / No phone

Status: Recruiting

Research Site

Barcelona, 08036, Spain

No email / No phone

Status: Recruiting

Research Site

Alicante, 03010, Spain

No email / No phone

Status: Recruiting

Research Site

Salamanca, 37007, Spain

No email / No phone

Status: Recruiting

Research Site

Reus,Tarragona, 43204, Spain

No email / No phone

Status: Recruiting

Research Site

Jerez de la Frontera, 11407, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 08003, Spain

No email / No phone

Status: Recruiting

Research Site

New Taipei City, 220, Taiwan

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 80756, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taichung, 40447, Taiwan

No email / No phone

Status: Recruiting

Research Site

Tainan City, 704, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 0116, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Taipei, 10002, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 112, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, TAIWAN, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Recruiting

Research Site

Mueang, 32000, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Mueang, 20000, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Muang, 22000, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Hat Yai, 90110, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Bangkok, 10400, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Antalya, 07070, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Ankara, 06560, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Ankara, 6200, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Adapazarı, 54100, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Istanbul, 34890, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Istanbul, 34030, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Diyarbakır, 21280, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Preston, PR2 9HT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SW10 9NH, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SE1 9RT, United Kingdom

No email / No phone

Status: Withdrawn

Research Site

Inverness, IV2 3UJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Cheltenham, GL53 7AN, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Truro, TR1 3LJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SW17 0QT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Anchorage, Alaska, 99508, United States

No email / No phone

Status: Recruiting

Research Site

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Research Site

Springdale, Arkansas, 72762, United States

No email / No phone

Status: Recruiting

Research Site

Little Rock, Arkansas, 72205, United States

No email / No phone

Status: Recruiting

Research Site

Fountain Valley, California, 92708, United States

No email / No phone

Status: Recruiting

Research Site

Anaheim, California, 92801, United States

No email / No phone

Status: Recruiting

Research Site

Beverly Hills, California, 90211, United States

No email / No phone

Status: Recruiting

Research Site

Newport Beach, California, 92663, United States

No email / No phone

Status: Not yet recruiting

Research Site

West Palm Beach, Florida, 33401, United States

No email / No phone

Status: Recruiting

Research Site

Clermont, Florida, 34711, United States

No email / No phone

Status: Recruiting

Research Site

Gainesville, Florida, 32608, United States

No email / No phone

Status: Recruiting

Research Site

Miami Beach, Florida, 33140, United States

No email / No phone

Status: Recruiting

Research Site

Orange City, Florida, 32763, United States

No email / No phone

Status: Recruiting

Research Site

Orlando, Florida, 32827, United States

No email / No phone

Status: Withdrawn

Research Site

Orlando, Florida, 32806, United States

No email / No phone

Status: Not yet recruiting

Research Site

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Withdrawn

Research Site

Atlanta, Georgia, 30322, United States

No email / No phone

Status: Recruiting

Research Site

Atlanta, Georgia, 30318, United States

No email / No phone

Status: Recruiting

Research Site

Atlanta, Georgia, 30303, United States

No email / No phone

Status: SUSPENDED

Research Site

Hinsdale, Illinois, 60521, United States

No email / No phone

Status: Not yet recruiting

Research Site

Noblesville, Indiana, 46062, United States

No email / No phone

Status: Recruiting

Research Site

Annapolis, Maryland, 21401, United States

No email / No phone

Status: Recruiting

Research Site

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Research Site

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Research Site

Traverse City, Michigan, 49684, United States

No email / No phone

Status: Withdrawn

Research Site

Dearborn, Michigan, 48126, United States

No email / No phone

Status: Recruiting

Research Site

Farmington Hills, Michigan, 48334, United States

No email / No phone

Status: Recruiting

Research Site

Grand Rapids, Michigan, 49503, United States

No email / No phone

Status: Recruiting

Research Site

Hattiesburg, Mississippi, 39401, United States

No email / No phone

Status: Recruiting

Research Site

Kansas City, Missouri, 64132, United States

No email / No phone

Status: Not yet recruiting

Research Site

Bozeman, Montana, 59715, United States

No email / No phone

Status: Withdrawn

Research Site

Omaha, Nebraska, 68130, United States

No email / No phone

Status: Recruiting

Research Site

Grand Island, Nebraska, 68803, United States

No email / No phone

Status: Recruiting

Research Site

Reno, Nevada, 89502, United States

No email / No phone

Status: Withdrawn

Research Site

Las Vegas, Nevada, 89102, United States

No email / No phone

Status: Recruiting

Research Site

Voorhees Township, New Jersey, 08043, United States

No email / No phone

Status: SUSPENDED

Research Site

Stony Brook, New York, 11794, United States

No email / No phone

Status: Recruiting

Research Site

Salisbury, North Carolina, 28144, United States

No email / No phone

Status: Not yet recruiting

Research Site

Greenville, North Carolina, 27834, United States

No email / No phone

Status: Not yet recruiting

Research Site

Cincinnati, Ohio, 45219, United States

No email / No phone

Status: Recruiting

Research Site

Columbus, Ohio, 43210, United States

No email / No phone

Status: Withdrawn

Research Site

Toledo, Ohio, 43608, United States

No email / No phone

Status: Not yet recruiting

Research Site

Portland, Oregon, 97213, United States

No email / No phone

Status: Withdrawn

Research Site

Greenville, South Carolina, 29607, United States

No email / No phone

Status: Recruiting

Research Site

Sioux Falls, South Dakota, 57105, United States

No email / No phone

Status: Recruiting

Research Site

Knoxville, Tennessee, 37920, United States

No email / No phone

Status: Withdrawn

Research Site

Chattanooga, Tennessee, 37404, United States

No email / No phone

Status: Withdrawn

Research Site

Fort Worth, Texas, 76104, United States

No email / No phone

Status: Recruiting

Research Site

Houston, Texas, 77030, United States

No email / No phone

Status: Withdrawn

Research Site

Houston, Texas, 77090, United States

No email / No phone

Status: SUSPENDED

Research Site

Odessa, Texas, 79761, United States

No email / No phone

Status: Recruiting

Research Site

Kingwood, Texas, 77339, United States

No email / No phone

Status: Recruiting

Research Site

Houston, Texas, 77030, United States

No email / No phone

Status: Not yet recruiting

Research Site

Leesburg, Virginia, 20176, United States

No email / No phone

Status: Recruiting

Research Site

Richmond, Virginia, 23230, United States

No email / No phone

Status: Recruiting

Research Site

Fort Belvoir, Virginia, 22060, United States

No email / No phone

Status: Not yet recruiting

Research Site

Wenatchee, Washington, 98801, United States

No email / No phone

Status: Recruiting

Research Site

Tacoma, Washington, 98405, United States

No email / No phone

Status: Recruiting

Research Site

Vancouver, Washington, 98684, United States

No email / No phone

Status: Recruiting

Research Site

Vinh, 460000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Hà Nội, 100000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Hanoi, 100000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Da Nang, 550000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Vĩnh Yên, 280000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Huế, 530000, Vietnam

No email / No phone

Status: Not yet recruiting

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Mechanism of action

Efficacy

Safety

Further reading

Show for: Rilvegostomig (AZD2936)

Overview

Mechanism of action

Efficacy

Safety

Key trials (selection)

Further reading

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (269)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site